FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials
European Journal of Cancer · 2025
DOI: 10.1016/j.ejca.2025.115713 ↗Kurz gefasst
Vergleichsstudie in der Zeitschrift European Journal of Cancer, 2025. Verfasst von Carlotta Antoniotti und 18 weiteren Autor:innen. Beteiligte Einrichtung: Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medic…. Hauptthemen laut MEDLINE: Antineoplastic Combined Chemotherapy Protocols, Bevacizumab, Colorectal Neoplasms, Liver Neoplasms. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 23 Literaturangaben.
Abstract (Originalsprache)
Kein Abstract verfügbar.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy; Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy.
- Department of Experimental and Clinical Medicine, University of Florence, Oncology Unit, Careggi University Hospital, Florence, Italy.
- Department Internal Medicine IV-Hematology-Oncology, Martin-Luther-University, Halle (Saale), Germany.
- Oncology 1 Unit Veneto Institute of Oncology IOV - IRCCS, Padova, Italy.
- Medical Oncology, Fondazione Policlinico Universitario Campus Bio-Medico, Roma, Italy; Department of Medicine and Surgery, Università Campus Bio-Medico di Roma, Roma, Italy.
- Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa, Italy.
Zitieren
APA
Antoniotti, C., Marmorino, F., Rossini, D., Schmoll, H. J., Lonardi, S., Tonini, G., Borelli, B., Cupini, S., Stein, A., Moretto, R., Bergamo, F., Ronzoni, M., Germani, M. M., Zaniboni, A., Fazio, R., De Grandis, M. C., Ongaro, E., Masi, G., & Cremolini, C. (2025). FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. https://doi.org/10.1016/j.ejca.2025.115713
Vancouver
Antoniotti C, Marmorino F, Rossini D, Schmoll HJ, Lonardi S, Tonini G, et al. FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials. European Journal of Cancer. 2025. doi:10.1016/j.ejca.2025.115713
BibTeX
@article{Antoniotti2025,
author = {Antoniotti, Carlotta and Marmorino, Federica and Rossini, Daniele and Schmoll, Hans Joachim and Lonardi, Sara and Tonini, Giuseppe and Borelli, Beatrice and Cupini, Samanta and Stein, Alexander and Moretto, Roberto and Bergamo, Francesca and Ronzoni, Monica and Germani, Marco Maria and Zaniboni, Alberto and Fazio, Roberta and De Grandis, Maria Caterina and Ongaro, Elena and Masi, Gianluca and Cremolini, Chiara},
title = {FOLFOXIRI/bevacizumab versus doublets/bevacizumab as initial therapy of unresectable liver-only, right-sided and/or RAS or BRAF mutated metastatic colorectal cancer: An individual patient data-based pooled analysis of randomized trials},
journal = {European Journal of Cancer},
year = {2025},
doi = {10.1016/j.ejca.2025.115713}
}
EUVIMED